Norges Bank’s Jade Biosciences JBIO Stock Holding History

Norges Bank’s Portfolio JBIO Stock Details JBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-2,900	Closed	-$1.2M	–	2174
2021 Q4	$1.2M	Buy	+2,900	New	+$1.47M	﹤0.01%	2088

Other funds holding JBIO

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

OMC

OUP Management Company Bala Cynwyd, Pennsylvania $44.5M AUM 55.11% 1-Year Est. Return

Norges Bank's JBIO Position: Q1 2022 in Review

Norges Bank sold out of Jade Biosciences (JBIO) in Q1 2022, closing a stake of 2,900 shares — an estimated $1.2M sold.

Norges Bank first reported a position in JBIO in Q4 2021 and held it in 1 quarter. The position peaked at $1.2M in Q4 2021. 45 funds tracked by Wall St. Rank hold JBIO as of Q1 2022.

Norges Bank reported no remaining Jade Biosciences position as of Q1 2022 after selling out during the quarter.
Norges Bank sold 2,900 Jade Biosciences shares in Q1 2022, an estimated $1.2M.
Norges Bank first reported a position in Jade Biosciences in Q4 2021 and held it in 1 quarter.
Norges Bank's Jade Biosciences position peaked at $1.2M in Q4 2021.
45 funds tracked by Wall St. Rank held Jade Biosciences as of Q1 2022.

Based on Norges Bank's 13F filing for Q1 2022, filed 9 May 2022.